WO2010127108A3 - Compositions comprising an antihistamine, antitussive and decongestant in extended release formulations - Google Patents

Compositions comprising an antihistamine, antitussive and decongestant in extended release formulations Download PDF

Info

Publication number
WO2010127108A3
WO2010127108A3 PCT/US2010/032958 US2010032958W WO2010127108A3 WO 2010127108 A3 WO2010127108 A3 WO 2010127108A3 US 2010032958 W US2010032958 W US 2010032958W WO 2010127108 A3 WO2010127108 A3 WO 2010127108A3
Authority
WO
WIPO (PCT)
Prior art keywords
decongestant
antitussive
antihistamine
extended release
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/032958
Other languages
French (fr)
Other versions
WO2010127108A2 (en
Inventor
James Joseph Mcdermott
R. Gary Hollenbeck
Craig Linwood Attkisson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atley Pharmaceuticals Inc
Original Assignee
Atley Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atley Pharmaceuticals Inc filed Critical Atley Pharmaceuticals Inc
Priority to JP2012508726A priority Critical patent/JP2012525424A/en
Priority to EP10770324A priority patent/EP2424534A2/en
Priority to CA2760689A priority patent/CA2760689A1/en
Publication of WO2010127108A2 publication Critical patent/WO2010127108A2/en
Anticipated expiration legal-status Critical
Publication of WO2010127108A3 publication Critical patent/WO2010127108A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides oral formulations for the treatment of cold and allergy symptoms. Each formulation combines an antihistamine, an antitussive, and/or a decongestant into one extended release composition. The invention further provides for methods of making and using such formulations, as well as for methods for preventing abuse or extraction of a single drug present in an oral extended release composition comprising two or more of an antihistamine, antitussive, and/or decongestant.
PCT/US2010/032958 2009-05-01 2010-04-29 Compositions comprising an antihistamine, antitussive and decongestant in extended release formulations Ceased WO2010127108A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2012508726A JP2012525424A (en) 2009-05-01 2010-04-29 Composition comprising antihistamine, antitussive and decongestant in sustained release preparation
EP10770324A EP2424534A2 (en) 2009-05-01 2010-04-29 Compositions comprising an antihistamine, antitussive and decongestant in extended release formulations
CA2760689A CA2760689A1 (en) 2009-05-01 2010-04-29 Compositions comprising an antihistamine, antitussive and decongestant in extended release formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17491209P 2009-05-01 2009-05-01
US61/174,912 2009-05-01

Publications (2)

Publication Number Publication Date
WO2010127108A2 WO2010127108A2 (en) 2010-11-04
WO2010127108A3 true WO2010127108A3 (en) 2014-03-27

Family

ID=43030858

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/032958 Ceased WO2010127108A2 (en) 2009-05-01 2010-04-29 Compositions comprising an antihistamine, antitussive and decongestant in extended release formulations

Country Status (5)

Country Link
US (1) US20100280059A1 (en)
EP (1) EP2424534A2 (en)
JP (1) JP2012525424A (en)
CA (1) CA2760689A1 (en)
WO (1) WO2010127108A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010127100A1 (en) * 2009-05-01 2010-11-04 Atley Pharmaceuticals, Inc. Compositions comprising an antihistamine, antitussive and decongestant in extented release formulations
WO2015166473A1 (en) 2014-05-01 2015-11-05 Sun Pharmaceutical Industries Limited Extended release suspension compositions
WO2018119413A1 (en) * 2016-12-22 2018-06-28 Lipidair, Llc Targeted delivery methods and compositions for antihistamines

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US20080292699A1 (en) * 2007-05-25 2008-11-27 Sovereign Pharmaceuticals, Ltd. Solid pharmaceutical dosage unit for alleviating symptoms of rhinorrhea
US20090081290A1 (en) * 2006-08-25 2009-03-26 Purdue Pharma L.P. Tamper resistant dosage forms

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US20060018972A1 (en) * 2002-11-26 2006-01-26 Upm Pharmaceuticals, Inc. Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
JP4808405B2 (en) * 2002-11-26 2011-11-02 ホ−レンベック ギャリ− ア−ル Aqueous sustained-release drug delivery system for highly water-soluble electrolyte drugs
US20070141147A1 (en) * 2005-12-21 2007-06-21 Auriga Laboratories, Inc. Sequential release pharmaceutical formulations
ATE536867T1 (en) * 2006-03-16 2011-12-15 Tris Pharma Inc MODIFIED RELEASE FORMULATIONS WITH DRUG ION EXCHANGE RESIN COMPLEXES
WO2008042218A1 (en) * 2006-10-03 2008-04-10 Tris Pharma, Inc. Formulations containing an ionic mineral-ion exchange resin complex and uses thereof
US20080085312A1 (en) * 2006-10-04 2008-04-10 Auriga Laboratories, Inc. Multi-Phase Release Potassium Guaiacolsulfonate Compositions
WO2010127100A1 (en) * 2009-05-01 2010-11-04 Atley Pharmaceuticals, Inc. Compositions comprising an antihistamine, antitussive and decongestant in extented release formulations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US20090081290A1 (en) * 2006-08-25 2009-03-26 Purdue Pharma L.P. Tamper resistant dosage forms
US20080292699A1 (en) * 2007-05-25 2008-11-27 Sovereign Pharmaceuticals, Ltd. Solid pharmaceutical dosage unit for alleviating symptoms of rhinorrhea

Also Published As

Publication number Publication date
WO2010127108A2 (en) 2010-11-04
US20100280059A1 (en) 2010-11-04
EP2424534A2 (en) 2012-03-07
CA2760689A1 (en) 2010-11-04
JP2012525424A (en) 2012-10-22

Similar Documents

Publication Publication Date Title
WO2010127100A8 (en) Compositions comprising an antihistamine, antitussive and decongestant in extended release formulations
WO2008085765A3 (en) Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
WO2010066749A3 (en) Ulipristal acetate tablets
WO2009121945A3 (en) Dpp-iv inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
WO2009121039A3 (en) Administration of benzodiazepine compositions
WO2007143155A3 (en) Sustained release pharmaceutical dosage form containing phenylephrine
WO2007103200A3 (en) Oral controlled release formulation for sedative and hypnotic agents
IL193762A (en) Compounds useful in inhibiting dgat1-related disorders, pharmaceutical compositions comprising them and use thereof in preparation of medicaments
WO2008011194A3 (en) Transmucosal delivery devices with enhanced uptake
WO2008122965A3 (en) Pharmaceutical cyclosporin compositions
WO2010132882A3 (en) Sublingual dexmedetomidine compositions and methods of use thereof
WO2008034041A3 (en) Therapeutic combinations
WO2009074351A3 (en) Solid forms of tenofovir disoproxil
WO2008146178A3 (en) A novel tablet dosage form
AP2012006231A0 (en) Capsule formulation of pirfenidone and pharmaceutically acceptable excipients.
CL2013001136A1 (en) A phosphodiesterase 7 (pde7) inhibitory agent to be used in the treatment or reduction of the possibility of an addiction; and pharmaceutical composition, unit dosage form and pharmaceutical kit including phosphodiesterase 7 inhibitor (pde7) and an additional therapeutic agent.
IL216006A (en) Substituted aromatic compounds, pharmaceutical compositions comprising them and use thereof in the manufacture of medications
CA2668320A1 (en) Use of 3-alpha-androstanediol, optionally in combination with a 5-ht1a agonist, in the treatment of sexual dysfunction
WO2009099467A3 (en) Cyclosporin compositions
WO2009068708A8 (en) Pharmaceutical composition with prolonged release of somatostatin or an analogue thereof
DK2448561T3 (en) Solid pharmaceutical solid dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic use
WO2009035634A3 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
WO2007131070A3 (en) Compositions, dosage forms and methods of treating emesis
WO2011047837A3 (en) Melt-granulated cinacalcet
WO2009149058A3 (en) Modified release niacin formulations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10770324

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2760689

Country of ref document: CA

Ref document number: 2012508726

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2010770324

Country of ref document: EP